Pre-made Mepolizumab benchmark antibody ( Whole mAb, anti-IL5 therapeutic antibody, Anti-EDF/IL-5/TRF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-341-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody
INN Name	Mepolizumab
Target	IL5
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	1999
Year Recommended	2000
Companies	GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases
Conditions Approved	Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome
Conditions Active	Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis
Conditions Discontinued	Atopic dermatitis
Development Tech	na